Vı́ctor Segarra

1.2k total citations
41 papers, 899 citations indexed

About

Vı́ctor Segarra is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Vı́ctor Segarra has authored 41 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 19 papers in Organic Chemistry and 8 papers in Pharmacology. Recurrent topics in Vı́ctor Segarra's work include Phosphodiesterase function and regulation (11 papers), Phenothiazines and Benzothiazines Synthesis and Activities (9 papers) and Synthesis and Biological Evaluation (6 papers). Vı́ctor Segarra is often cited by papers focused on Phosphodiesterase function and regulation (11 papers), Phenothiazines and Benzothiazines Synthesis and Activities (9 papers) and Synthesis and Biological Evaluation (6 papers). Vı́ctor Segarra collaborates with scholars based in Spain, Italy and Mexico. Vı́ctor Segarra's co-authors include José Palacios, Teresa Domènech, Jörge Beleta, José María Huerta, Hamish Ryder, Montserrat Miralpeix, Clara Ràfols, Sònia Espinosa, Elisabeth Bosch and Martı́ Rosés and has published in prestigious journals such as PLoS ONE, Scientific Reports and Environmental Pollution.

In The Last Decade

Vı́ctor Segarra

41 papers receiving 857 citations

Peers

Countries citing papers authored by Vı́ctor Segarra

Since Specialization

Citations

This map shows the geographic impact of Vı́ctor Segarra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vı́ctor Segarra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vı́ctor Segarra more than expected).

Fields of papers citing papers by Vı́ctor Segarra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vı́ctor Segarra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vı́ctor Segarra. The network helps show where Vı́ctor Segarra may publish in the future.

Co-authorship network of co-authors of Vı́ctor Segarra

This figure shows the co-authorship network connecting the top 25 collaborators of Vı́ctor Segarra. A scholar is included among the top collaborators of Vı́ctor Segarra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vı́ctor Segarra. Vı́ctor Segarra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combining machine‐learning and molecular‐modeling methods for drug‐target affinity predictions 2022 ·Wiley Interdisciplinary Reviews Computational Molecular Science ·(unknown), (unknown), (unknown), Vı́ctor Segarra, (unknown), Vı́ctor Guallar	7
2	Integrating multiple lines of evidence to assess freshwater ecosystem health in a tropical river basin 2021 ·Environmental Pollution ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Vı́ctor Segarra, (unknown), (unknown), Rodrigo Espinosa, Marcela Cabrera, Mariana V. Capparelli, Jorge Celi	5
3	Atomistic simulations shed new light on the activation mechanisms of RORγ and classify it as Type III nuclear hormone receptor regarding ligand-binding paths 2019 ·Scientific Reports ·Suwipa Saen‐oon, (unknown), Vı́ctor Segarra, Vı́ctor Guallar, Robert Soliva	9
4	Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells 2018 ·PLoS ONE ·Adelina Orellana, Vicente García‐González, Rosa López-Gigosos, (unknown), (unknown), Julia E. Sepúlveda-Díaz, (unknown), (unknown), (unknown), (unknown), Vı́ctor Segarra, Dolors Vilella, Rajneesh Malhotra, Paul Eastwood, Anna Planagumà, Montserrat Miralpeix, Arsenio Nueda	8
5	Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation 2015 ·Pulmonary Pharmacology & Therapeutics ·Anna Planagumà, Teresa Domènech, (unknown), Elena Calama, Vicente García‐González, Rosa López-Gigosos, Mariona Aulí, Manuel López, Sı́lvia Fonquerna, Israel Ramos, J. De Alba, Arsenio Nueda, Neus Prats, Vı́ctor Segarra, Montserrat Miralpeix, Manfred Lehner	37
6	Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts 2015 ·European Journal of Pharmaceutical Sciences ·(unknown), Martı́ Rosés, Clara Ràfols, Elisabeth Bosch, Sònia Espinosa, Vı́ctor Segarra, José María Huerta	160
7	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides as potent and long acting muscarinic antagonists 2015 ·Bioorganic & Medicinal Chemistry Letters ·María Prat, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Amadeu Gavaldà, Montserrat Miralpeix, Israel Ramos, Dolors Vilella, José María Huerta, Sònia Espinosa, (unknown), Vı́ctor Segarra, (unknown)	9
8	Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors 2013 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Carolina Burgos, Juan J. Vaquero, Julio Álvarez‐Buílla, (unknown), Vı́ctor Segarra	35
9	Discovery of a novel class of zwitterionic, potent, selective and orally active S1P1 direct agonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), (unknown), Manel López, Vı́ctor Segarra, (unknown), (unknown), Núria Godessart, Gema Tarrasón, Teresa Domènech, Dolors Vilella, (unknown), (unknown), (unknown), (unknown), (unknown)	4
10	1,3-Dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure–affinity and structure–selectivity relationships 2009 ·Bioorganic & Medicinal Chemistry ·Franco Fernández, Olga Caamaño, Marı́a Isabel Nieto, Carmen López, Xerardo García‐Mera, Angela Stefanachi, Orazio Nicolotti, Marı́a Isabel Loza, José Brea, (unknown), Vı́ctor Segarra, Bernat Vidal, Angelo Carotti	11
11	Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2′-furyl)-1,2,4-triazolo[1,5-a]quinoxalines 2008 ·Bioorganic & Medicinal Chemistry ·Ana Martı́nez, Hugo Gutiérrez‐de‐Terán, José Brea, Enrique Raviña, Marı́a Isabel Loza, Marı́a Isabel Cadavid, Ferrán Sanz, Bernat Vidal, Vı́ctor Segarra, Eddy Sotelo	15
12	Combinatorial approaches towards the discovery of new tryptase inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Dolors Fernández‐Forner, Montserrat Miralpeix, Vı́ctor Segarra, Hamish Ryder, Míriam Royo, Fernando Alberício	11
13	Design, synthesis and biological activity of a targeted library of potential tryptase inhibitors 2004 ·Organic & Biomolecular Chemistry ·Mónica Garcı́a, (unknown), (unknown), Mario Rubiralta, (unknown), Vı́ctor Segarra, (unknown), Montserrat Miralpeix, Mònica Aparici, Anna Diez	5
14	Molecular Diversity Sample Generation on the Basis of Quantum-Mechanical Computations and Principal Component Analysis 2002 ·Combinatorial Chemistry & High Throughput Screening ·Hugo Gutiérrez‐de‐Terán, Juan José Lozano, Vı́ctor Segarra, Ferrán Sanz	3
15	Synthesis and Evaluation of Some Pyrazolo[3,4-d]pyridazinones and Analogues as PDE 5 Inhibitors Potentially Useful as Peripheral Vasodilator Agents 2002 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Vittorio Dal Piaz, (unknown), Claudia Vergelli, Maria Paola Giovannoni, Amadeu Gavaldà, Vı́ctor Segarra, Jörge Beleta, Hamish Ryder, José María Fernández Palacios	22
16	Synthesis and biological evaluation of 2,5-dihydropyrazolo[4,3-c]quinolin-3-ones, a novel series of PDE 4 inhibitors with low emetic potential and antiasthmatic properties 2000 ·Bioorganic & Medicinal Chemistry Letters ·M. Crespo, (unknown), (unknown), Armando Vega, Josep Bou, Jordi Beleta, Teresa Domènech, Hamish Ryder, Vı́ctor Segarra, José Palacios	29
17	Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and Terfenadine 1999 ·Drug Safety ·Vı́ctor Segarra, (unknown), Hamish Ryder, (unknown), David Roberts	7
18	Synthesis and biological evaluation of a conformationally free seco-analogue of the immunosuppressant FR901483 1999 ·Bioorganic & Medicinal Chemistry ·Josep Bonjoch, Fai͏̈za Diaba, (unknown), Daniel Solé, Vı́ctor Segarra, Luis F. Santamaria‐Babí, Jörge Beleta, Hamish Ryder, José Palacios	14
19	Novel Heterocyclic-Fused Pyridazinones as Potent and Selective Phosphodiesterase IV Inhibitors 1997 ·Journal of Medicinal Chemistry ·Vittorio Dal Piaz, Maria Paola Giovannoni, (unknown), José María Fernández Palacios, Jörge Beleta, Teresa Domènech, Vı́ctor Segarra	62
20	Degradation profile and identification of the major degradation products of dobupride under several conditions by GC/MS and HPLC-particle beam/MS 1995 ·Journal of Pharmaceutical and Biomedical Analysis ·Vı́ctor Segarra, (unknown), J. Fábregas, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact